High Prevalence of Likely Passively Acquired Anti-TPO and Anti-GAD Autoantibodies in Common Variable Immunodeficiency

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22330%2F21%3A43922209" target="_blank" >RIV/60461373:22330/21:43922209 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/22:10434130 RIV/00064203:_____/22:10434130 RIV/00216208:11110/22:10434130

Výsledek na webu

<a href="https://link-springer-com.ezproxy.vscht.cz/article/10.1007%2Fs10875-021-01171-8" target="_blank" >https://link-springer-com.ezproxy.vscht.cz/article/10.1007%2Fs10875-021-01171-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10875-021-01171-8" target="_blank" >10.1007/s10875-021-01171-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

High Prevalence of Likely Passively Acquired Anti-TPO and Anti-GAD Autoantibodies in Common Variable Immunodeficiency

Popis výsledku v původním jazyce

Common variable immunodeficiency disorder (CVID) is one of the most frequent inborn errors of immunity characterized by decreased immunoglobulin production, impaired specific antibody response, and higher susceptibility to infections along with immune system dysregulation and higher prevalence of non-infectious complications [1]. Despite the markedly impaired antibody production, diseases hallmarked by the presence of autoantibodies, such as autoimmune hemolytic anemia (AIHA) or immune thrombocytopenic purpura (ITP), are among the most commonly diagnosed autoimmune complications in CVID patients [2]. The mainstay of CVID management is a regular, long-term immunoglobulin replacement therapy (IRT). Importantly, the immunoglobulin solutions used for IRT were shown to contain various specific antibodies and may even be responsible for IRT-associated adverse events, such as self-limiting acute hemolysis triggered by passivelly transmitted antierythrocyte alloantibodies [3]. Therefore, we initiated a prospective observational trial to determine the prevalence, clinical significance, and origin of the spectrum of autoantibodies in CVID patients on IRT.

Název v anglickém jazyce

High Prevalence of Likely Passively Acquired Anti-TPO and Anti-GAD Autoantibodies in Common Variable Immunodeficiency

Popis výsledku anglicky

Common variable immunodeficiency disorder (CVID) is one of the most frequent inborn errors of immunity characterized by decreased immunoglobulin production, impaired specific antibody response, and higher susceptibility to infections along with immune system dysregulation and higher prevalence of non-infectious complications [1]. Despite the markedly impaired antibody production, diseases hallmarked by the presence of autoantibodies, such as autoimmune hemolytic anemia (AIHA) or immune thrombocytopenic purpura (ITP), are among the most commonly diagnosed autoimmune complications in CVID patients [2]. The mainstay of CVID management is a regular, long-term immunoglobulin replacement therapy (IRT). Importantly, the immunoglobulin solutions used for IRT were shown to contain various specific antibodies and may even be responsible for IRT-associated adverse events, such as self-limiting acute hemolysis triggered by passivelly transmitted antierythrocyte alloantibodies [3]. Therefore, we initiated a prospective observational trial to determine the prevalence, clinical significance, and origin of the spectrum of autoantibodies in CVID patients on IRT.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Immunology

ISSN

0271-9142

e-ISSN

—

Svazek periodika

42

Číslo periodika v rámci svazku

listopad

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

427-429

Kód UT WoS článku

000718223900001

EID výsledku v databázi Scopus

2-s2.0-85119409581